Hopganc 500

Hopganc 500 is an antiviral injectable formulation that consists of Ganciclovir 500 mg marketed by Diya Healthcare. It is an antiviral medicine that slows down cytomegalovirus DNA polymerase and is used in certain clinical situation including CMV infection specifically in immunocompromised patients. Ganciclovir injection is given intravenously under the supervision of certified healthcare professionals.

Composition of Hopganc 500

Each vial contains:
Ganciclovir 500 mg

Ganciclovir belongs to the antiviral class of medicines. It works by preventing viral DNA synthesis thus slowing down the replication of susceptible cytomegalovirus. The medicine is specifically related to patients whose immune systems are weakened and who are at maximum risk of serious CMV related complications.

Uses of Hopganc 500

Ganciclovir injection may be used for the treatment of CMV retinitis in immunocompromised adults and for the prevention of CMV disease in adult transplant recipients who are at risk.

CMV is a common viral infection that may remain inactive in healthy individuals but can cause significant disease in people with weakened immune systems. Patients undergoing organ transplantation or those with certain immunocompromising conditions may require antiviral therapy when CMV infection or disease develops or when prevention is clinically indicated.

Hopganc 500 should be used only for an appropriate medical indication determined by a healthcare professional. It is not intended for routine treatment of ordinary viral infections such as the common cold or influenza.

How Hopganc 500 Works?

Ganciclovir is a nucleoside analogue antiviral agent that inhibits CMV DNA polymerase. By interfering with viral DNA synthesis, it helps suppress the replication of CMV and can reduce viral activity in appropriate patients.

The dose and duration of treatment are individualized according to the patient’s condition, treatment objective, kidney function, and other clinical factors. Patients with renal impairment generally require dosage adjustment because ganciclovir is cleared through the kidneys.

Administration

Hopganc 500 is intended for intravenous administration by qualified healthcare professionals. The medicine should be prepared and administered according to the approved prescribing information and institutional protocols.

Patients should not attempt to administer this medicine themselves. Healthcare professionals may monitor blood counts and kidney function during treatment because ganciclovir can cause significant haematological and renal adverse effects.

Precautions and Safety Information

Ganciclovir treatment requires appropriate medical supervision. Important risks include neutropenia, anaemia, thrombocytopenia, and pancytopenia. Regular complete blood counts may therefore be required during therapy. Renal function should also be monitored, particularly in patients with existing kidney impairment or those receiving medicines that may affect renal function.

Patients should inform their healthcare provider about existing medical conditions, allergies, pregnancy or plans for pregnancy, and all medicines they are taking. Ganciclovir has important reproductive and fetal safety warnings based on animal data, so appropriate medical advice is essential before treatment.

FAQs About Hopganc 500

1. What is Hopganc 500 used for?

Hopganc 500 contains Ganciclovir 500 mg and may be used for specific CMV-related conditions, including CMV retinitis in immunocompromised adults and prevention of CMV disease in certain adult transplant recipients at risk.

2. What is the composition of Hopganc 500?

Hopganc 500 contains Ganciclovir 500 mg as its active pharmaceutical ingredient.

3. Is Hopganc 500 an antiviral medicine?

Yes. Ganciclovir is an antiviral medicine that inhibits CMV DNA polymerase and interferes with viral DNA synthesis.

4. How is Hopganc 500 administered?

Hopganc 500 is intended for intravenous administration by a qualified healthcare professional.

5. Can Hopganc 500 be self-administered?

No. It should be administered only by trained healthcare professionals in an appropriate medical setting.

6. Does the dose of Hopganc 500 need to be adjusted in kidney problems?

Yes. Ganciclovir dosing should be adjusted according to renal function because impaired kidney function can increase exposure to the medicine.